[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mao Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100651686","bedside-nt-probnp-monitoring-in-acute-heart-failure-100651686",false,"NCT07762521","Bedside NT-proBNP Monitoring in Acute Heart Failure","Impact of Serial Point-of-Care NT-proBNP Monitoring on Decongestion in Acute Decompensated Heart Failure: A Prospective Controlled Study","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Patients hospitalized in the cardiac intensive care unit (CCU) with a diagnosis of acute decompensated heart failure (ADHF).\n* Presence of clinical evidence of congestion at admission, including at least one of the following:\n* Symptoms or signs of volume overload (e.g., dyspnea, orthopnea, peripheral edema, elevated jugular venous pressure).\n* Pulmonary congestion based on physical examination or imaging findings.\n* Other clinically recognized evidence of congestion judged by the treating physician.\n* Patients receiving standard guideline-directed medical treatment for acute decompensated heart failure, including intravenous diuretic therapy according to clinical practice.\n* Ability to provide informed consent or availability of a legally authorized representative to provide consent.\n\nExclusion Criteria:\n\n* Cardiogenic shock or requirement for immediate mechanical circulatory support.\n* End-stage kidney disease requiring maintenance dialysis or renal replacement therapy at admission.\n* Acute conditions requiring urgent intervention that may interfere with study assessments, including acute coronary syndrome requiring immediate revascularization or acute pulmonary embolism.\n* Clinical conditions in which NT-proBNP interpretation is considered unreliable or inappropriate by the investigator.\n* Expected survival of less than 72 hours, early transfer from the CCU, or inability to complete the core observation period.\n* Any other condition considered inappropriate for participation by the investigator.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to investigate the association between dynamic changes in NT-proBNP levels and clinical decongestion status in patients with acute decompensated heart failure (ADHF) receiving guideline-directed standard medical treatment.\n\nThe main question it aims to answer is:\n\nAmong patients with acute decompensated heart failure treated according to current clinical guidelines, are changes in NT-proBNP levels during hospitalization associated with successful clinical decongestion?\n\nParticipants will receive standard-of-care treatment for ADHF according to treating physicians' clinical decisions and current guideline recommendations. During hospitalization, serial NT-proBNP measurements and repeated assessments of congestion status will be performed to evaluate the relationship between NT-proBNP dynamics and the process of decongestion.\n\nThis study is purely observational and will not assign treatments or modify clinical management. The findings may improve understanding of the role of NT-proBNP dynamics as a marker of treatment response and provide preliminary evidence for future studies on individualized management of acute heart failure.",[25],"Acute Decompensated Heart Failure (ADHF)",[27,28],"ADHF","POCT NT-proBNP","NOT_YET_RECRUITING","2026-08-08",{"date":32,"type":33},"2026-08-13","ACTUAL",{"date":35,"type":20},"2026-08-15",{"date":37,"type":20},"2026-12-30",{"name":39,"class":40},"Mao Chen","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100650243","ablation-with-transcatheter-edge-to-edge-repair-for-atrial-functional-mitral-regurgitation-and-atrial-fibrillation-100650243","NCT07744035","Ablation With Transcatheter Edge-to-edge Repair for Atrial Functional Mitral Regurgitation and Atrial Fibrillation","Ablation wiTh TRAnsCatheter Edge-to-edge Repair Versus ablaTION Alone for Atrial Functional Mitral Regurgitation and Atrial Fibrillation (ATTRACTION Study)","ATTRACTION","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Left ventricular ejection fraction ≥ 50%\n* Grading of MR: 3+ or 4+ (effective regurgitant orifice area≥30mm2, regurgitant volume ≥45ml)\n* Valve morphology: MR originating from the mid portion of the valve; mitral valve area\\> 4 cm2; Length of posterior leaflet ≥10 mm; Sufficient leaflet tissue for mechanical coaptation: coaptation depth\\\u003C 11 mm, coaptation length\\> 2 mm\n* Rate control in suspected AF-induced cardiomyopathy (heart rate \\\u003C80 bpm at rest and \\\u003C110 bpm during exercise)\n* Patients must be willing to comply with all follow-up requirements\n\nExclusion Criteria:\n\n* Life expectancy\\\u003C 1 year due to non-cardiac conditions\n* Primary mitral regurgitation: valve abnormalities including leaflet tethering from LV dysfunction, intrinsic leaflet pathology (prolapse, flail, calcification, severe thickening), mitral annular calcification (either severe or \\\u003Csevere but extending into the leaflets), and\u002For any mixed pathology\n* Active endocarditis of the mitral valve or rheumatic mitral valve disease\n* Hypotension (systolic pressure \\\u003C 90 mmHg) or requirement for inotropic support or mechanical hemodynamic support\n* Severe tricuspid regurgitation; Physical evidence of right-sided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction; Fixed pulmonary artery systolic pressure\\> 70 mmHg\n* Stroke\u002FTIA, TAVR, CRT\u002F CRT-D\u002F ICD, cardiac intervention or surgery within 30 days before randomization\n* Any prior MV surgery or transcatheter procedure\n* Need for any cardiac surgery (other than for MV disease)\n* Untreated clinically significant coronary artery disease\n* Echocardiographic evidence of intracardiac thrombus\n* Active infections requiring current antibiotic therapy\n* Patients who cannot tolerate anti-platelet\u002Fanticoagulation agents\u002Fcontrast media\n* Pregnancy\n* Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with medical therapy) and follow-up visits\n* Patient (or legal guardian) unable or unwilling to provide written informed consent before study enrollment",{"count":50,"type":20},384,"INTERVENTIONAL",[53],"NA","This trial is a randomized study for patients with significant atrial functional mitral regurgitation (AFMR) and atrial fibrillation (AF). The composite endpoint of all-cause mortality, cardiovascular-related hospitalizations, AF recurrence, and quality of life improvement is hypothesized to be superior with the combination of transcatheter edge-to-edge repair (TEER) and catheter ablation, compared with catheter ablation alone.",[56,57],"Atrial Functional Mitral Regurgitation","Atrial Fibrillation (AF)",[59,60],"Transcatheter edge to edge repair","Catheter ablation","2026-08-02",{"date":63,"type":33},"2026-08-04",{"date":65,"type":20},"2026-09-01",{"date":67,"type":20},"2029-09-01",{"name":39,"class":40},""]